How the LUNA-FX7 is helping clinical researchers to improve cancer patient outcomes

2021-08-05

May 25, 2021

 

How the LUNA-FX7 is helping clinical researchers to improve cancer patient outcomes

 

The new LUNA-FX7™ Automated Cell Counter has been highlighted as a key tool in groundbreaking efforts to advance precision medicine.

 

Researchers at Proteona have been using the latest addition to the LUNA™ family in their work around single-cell multi-omic analysis.

 

Through a combination of innovative single-cell assays and AI-assisted bioinformatics, Proteona enables the integration of this single-cell level precision into cancer research.

 

“We have already seen multiple instances where our technologies have added tremendous value to research focused on identifying the optimal treatment of cancer patients,” says Associate Research Scientist Ray Wang.

 

Key to this pioneering work is the LUNA-FX7™, as Wang explains in an interview with leading independent science publisher SelectScience.

 

“It is important to us to be able to control the number of cells we are loading into the droplet generator so that we maintain a high level of droplets that contain single cells, while also making sure not to underload and lose out on potentially important data,” says Wang.

 

“The LUNA-FX7 is a great addition to our workflow and helps us more easily batch process samples.”

 

Find out more about Proteona’s work and the part played by Logos Biosystems’ LUNA-FX7™ in the full article here>>

 



LUNA-FX7™ Automated Cell Counter

list